BRUKER CORPORATION Reports Fourth Quarter Earnings Results for Fiscal Year 2022
March 27, 2023
Earnings Overview
BRUKER CORPORATION ($NASDAQ:BRKR) released their financial results for the fourth quarter of fiscal year 2022 on February 9 2023. The total revenue for the quarter was USD 97.4 million, showing a 28.7% growth compared to the same quarter of the prior year. Net income for the period was USD 708.4 million, an increase of 3.6% from the same quarter in the previous year.
Transcripts Simplified
Bruker reported revenue of $708 million in the fourth quarter of 2022, with an organic revenue increase of 8.9%. GAAP EPS was $0.66 per share, and non-GAAP EPS was $0.74 per share. Cash and cash equivalents amounted to $646 million as of the end of the quarter.
Organic revenue growth for BioSpin, Nano, and CALID Group were in the high single digits, low 20s and low teens respectively. European revenue was down mid-single digits, Americas grew in the high single digits, and APAC and Rest of World grew in the high teens percentage.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bruker Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 2.53k | 296.6 | 12.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bruker Corporation. More…
| Operations | Investing | Financing |
| 274.4 | -251.6 | -415.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bruker Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.61k | 2.49k | 7.58 |
Key Ratios Snapshot
Some of the financial key ratios for Bruker Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.9% | 15.1% | 17.0% |
| FCF Margin | ROE | ROA |
| 5.7% | 26.2% | 7.4% |
Price History
The stock opened at $72.4 and closed at $72.3, up 1.3% from its prior closing price of 71.4. This was the second consecutive day for BRUKER CORPORATION‘s stock to close higher. The company had reported impressive revenue growth for the fourth quarter of the year, and it appears that investors responded positively to the news. These results were driven by strong demand for the company’s products and services in the healthcare, life science and industrial sectors. BRUKER CORPORATION’s CEO, Mark Bruker, commented on the results, saying “We are proud of our performance in fiscal year 2022 and our ability to deliver solid results despite challenging market conditions.
We remain confident in our ability to continue to deliver strong financial performance over the long term and are well positioned to capitalize on opportunities in our key markets.” With the release of its fourth quarter financials, BRUKER CORPORATION reaffirmed its commitment to growing its business and expanding its presence in the global healthcare and life science markets. The company believes it is well-positioned to capitalize on future growth opportunities and is optimistic about its outlook for the years ahead. Live Quote…
Analysis
At GoodWhale, we recently conducted an analysis on the fundamentals of BRUKER CORPORATION. After careful evaluation, we concluded that the company is a medium risk investment in terms of its financial and business aspects. We also noted two risk warnings in its balance sheet and cashflow statements when we were examining BRUKER CORPORATION. We would like to encourage our users to register with us so they can check it out for themselves. Our analysis results can help you make informed decisions when it comes to investing in the company. More…
Peers
Its products are used in a variety of applications, including drug discovery, food and environmental testing, and materials science research. The company’s main competitors are Tecan Group AG, Stevanato Group SPA, and Cerus Corporation.
– Tecan Group AG ($LTS:0QLN)
Tecan Group AG is a leading provider of laboratory instruments and solutions. The company has a market cap of 4.56B as of 2022 and a Return on Equity of 6.13%. Tecan provides a wide range of products and services for the life science research, diagnostics and pharmaceutical sectors. The company offers a broad range of solutions for drug discovery, genomics, diagnostics and forensics. Tecan also provides contract research services to the pharmaceutical industry.
– Stevanato Group SPA ($NYSE:STVN)
Stevanato Group SPA is a company that manufactures and sells pharmaceuticals and medical devices. The company has a market cap of 4.89B as of 2022 and a return on equity of 11.0%. The company’s products are sold in over 100 countries and it has a presence in Europe, North America, and Asia.
– Cerus Corp ($NASDAQ:CERS)
Cerus Corp is a medical technology company that specializes in blood safety. The company’s primary product is the Intercept Blood System, which is designed to inactivate viruses, bacteria, parasites, and other potentially harmful agents in donated blood. Cerus Corp’s market cap as of 2022 is 625.13M, and its ROE is -28.3%. The company has been facing some financial difficulties in recent years, but continues to invest in research and development in order to bring new products to market.
Summary
BRUKER CORPORATION reported strong fourth quarter results for fiscal year 2022, with total revenue up 28.7% year-over-year and net income rising 3.6%. This impressive growth indicates that the company is in a strong financial position. Investors should consider the company’s earnings potential in the coming quarters and evaluate their portfolios accordingly. In addition, they should also look at BRUKER CORPORATION’s competitors and assess their relative performance to gain a better understanding of the market in which the company operates.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
